Stock Events

Charles River Laboratories International 

€169.75
63
-€0.1-0.06% Heute

Statistik

Tag Hoch
169.75
Tag Tief
169.75
52W Hoch
-
52W Niedrig
-
Volumen
0
Durch. Volumen
-
Marktkap.
10.21B
KGV
23.65
Dividendenrendite
-
Dividende
-

Demnächst

Gewinne

30OctErwartet
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Weiter
1.91
2.13
2.35
2.56
Erwartetes EPS
2.18761416616
Tatsächliches EPS
K.A.

Leute folgen auch

Diese Liste basiert auf den Watchlists von Personen auf Stock Events, die RV6.F folgen. Es handelt sich nicht um eine Anlageempfehlung.

Wettbewerber

Diese Liste ist eine Analyse basierend auf aktuellen Marktereignissen. Es ist keine Anlageempfehlung.

Analystenbewertungen

219.88Durchschnittliches Kursziel
Die höchste Schätzung ist €250.
Von 9 Bewertungen innerhalb der letzten 6 Monate. Dies ist keine Anlageempfehlung.
Kaufen
33%
Halten
67%
Verkaufen
0%

Über

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Show more...
CEO
Mr. James C. Foster J.D.
Mitarbeiter
20400
Land
US
ISIN
US1598641074
WKN
000939391

Börsen